Regenerative Medicine

As Claris Bio courts investors, it's not just capital on the line. At stake is a first-of-its-kind eye drop for a rare, blinding disease.

The Israeli biotech firm gained crucial FDA feedback for its personalized therapy, NewRal. But in a field laden with failure, is this a true breakthrough?

Thai researchers are turning fat into insulin-producing cells to cure pet diabetes. But can this breakthrough navigate the path from lab to leash?

A German biotech's novel drug just won a key FDA designation, a strategic move that could redefine the limits of liver surgery and cancer treatment.

As Mesoblast prepares its year-end webcast, investors weigh a stellar $115M Ryoncil launch against cash burn and the high-stakes progress of its next-gen therapies.

A proposed SXSW panel on longevity medicine forces a crucial question: Are we on the verge of restoring youth, or just drowning in promises? We look at the science.

BioLab Holdings partners with mimiX AWC, bringing a radical new technology to market that uses a patient's own blood to create a living, healing patch.

New preclinical data shows NurExone's ExoPTEN protects vital nerve coatings, providing a biological basis for functional recovery in spinal cord injury models.

With key FDA backing and promising clinical data, Allogene Therapeutics is advancing a vision where complex cell therapies are not just for major medical centers.

BioCardia secures key regulatory backing in the US and Japan, but the real story may be its pivot to a platform provider for the entire cardiac biologics field.

With breakthrough dialysis data and a new heart-mending vessel, Humacyte is balancing radical innovation with commercial reality. Is this the future of medicine?

BioStem Technologies' move from OTC to Nasdaq marks a pivotal moment, promising greater capital access and visibility for its innovative perinatal allografts.

A landmark study on equicenta® CTM shows it nearly triples a horse's odds of returning to performance, offering a ready-to-use solution that challenges the status quo.

A French biotech's breakthrough in topical mRNA delivery could turn skin into a programmable interface, disrupting dermatology and the multi-billion dollar beauty industry.

A revenue dip masks a calculated pivot. UTHR is betting its future not just on new drugs, but on a revolutionary plan to manufacture human organs.

By assembling a 'dream team' of scientific advisors, INmune Bio isn't just advancing a drug; it's fortifying the very structure of cell therapy development.

A new study on umbilical cord allografts offers hope for chronic neck pain, but a closer look reveals the complex scientific and regulatory networks that will define its future.

A Cleveland-based innovator rebrands, signaling a major shift from passive wound care to active biomaterials designed to guide regeneration and defeat infection.

Pluri's subsidiary Cellav just won UK approval for its aesthetic product. But the real story is the science and a market potentially 4x larger than stated.

Pacira BioSciences de-risks its promising knee osteoarthritis gene therapy by solving the manufacturing puzzle, a key step from lab to market for millions.